AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21914242 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal psychological intervention (MPI)
Number of subjects: 361
Study 21914242 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 361
Study 20374547 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 1 (preprocedure measurement using CXR)
Number of subjects: 291
Study 20374547 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 2 (preprocedure measurement using CXR)
Number of subjects: 291
Study 20374547 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 1 (preoperative supine CXR)
Number of subjects: 291
Study 20374547 — intervention group
Group type: EXPERIMENTAL
Intervention: Method 2 (preoperative supine CXR)
Number of subjects: 291
Study 18165459 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 264
Study 18165459 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 16159618 — intervention group
Group type: EXPERIMENTAL
Intervention: ASHMI group (oral ASHMI capsules and prednisone placebo tablets)
Number of subjects: 91
Study 16159618 — intervention group
Group type: COMPARATOR
Intervention: Prednisone group (oral prednisone tablets and ASHMI placebo capsules)
Number of subjects: 91
Study 12669132 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of n-3 polyunsaturated fatty acids (PUFAs)
Number of subjects: 300
Study 12669132 — intervention group
Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 300
Study 12669132 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose of n-3 PUFAs
Number of subjects: 300
Study 12669132 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional statin treatment
Number of subjects: 300
Study 10550467 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg once daily for 1 year
Number of subjects: 1908
Study 10550467 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1908
Study 8727863 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg twice daily
Number of subjects: 398
Study 8727863 — intervention group
Group type: COMPARATOR
Intervention: Sulfadiazine 500 mg/Trimethoprim 160 mg twice daily
Number of subjects: 398
Study 8348278 — intervention group
Group type: EXPERIMENTAL
Intervention: Active laser treatment (CB Medico Master III 830 nm Ga As AL diode)
Number of subjects: 35
Study 8348278 — intervention group
Group type: COMPARATOR
Intervention: Dummy laser treatment
Number of subjects: 35
Study 3528278 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal saline plus hydrocortisone (100 mg daily)
Number of subjects: 13
Study 3528278 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (1 l/day)
Number of subjects: 13
Study 29239772 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) program
Number of subjects: 100
Study 29239772 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 100
Study 27367723 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium‐bicarbonated mineral water (BW)
Number of subjects: 64
Study 27367723 — intervention group
Group type: COMPARATOR
Intervention: Control mineral water low in mineral content (CW)
Number of subjects: 64
Study 23484910 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with virgin olive oil (MED + VOO)
Number of subjects: 564
Study 23484910 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts (MED + nuts)
Number of subjects: 564
Study 23484910 — intervention group
Group type: COMPARATOR
Intervention: Control low-fat diet
Number of subjects: 564
Study 21934310 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmoking model pressuring not to smoke
Number of subjects: 59
Study 21934310 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmoking peers verbally pressuring not to smoke
Number of subjects: 59
Study 21934310 — intervention group
Group type: COMPARATOR
Intervention: Heavy‐smoking model not using any pressure
Number of subjects: 59
Study 21934310 — intervention group
Group type: COMPARATOR
Intervention: Nonsmoking peers not verbally pressuring
Number of subjects: 59
Study 19608816 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified method using a retractable carinal hook (hook group, n = 20)
Number of subjects: 40
Study 19608816 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (conventional group, n = 20)
Number of subjects: 40
Study 19608816 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified method using a retractable carinal hook (hook group)
Number of subjects: 40
Study 19608816 — intervention group
Group type: COMPARATOR
Intervention: Conventional method (conventional group)
Number of subjects: 40
Study 19608816 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 17512232 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (rhGH) 0.019 mg kg(‐1) day(‐1) for 6 days
Number of subjects: 48
Study 17512232 — intervention group
Group type: COMPARATOR
Intervention: Control group (abstinent AAS users)
Number of subjects: 48
Study 15459211 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 60 mg/m² plus cisplatin 50 mg/m² every 3 weeks
Number of subjects: 281
Study 15459211 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin 60 mg/m²
Number of subjects: 281
Study 11441776 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9210675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally every 12 hours
Number of subjects: 12
Study 9210675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 mg intravenously
Number of subjects: 12
Study 9210675 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (both routes)
Number of subjects: 12
Study 8135686 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video shown to randomly assigned group of Veteran hospital psychiatric patients
Number of subjects: 0
Study 8135686 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall attitudes towards ECT in all three groups (psychiatric patients, non-psychiatric patients, general hospital patients)
Number of subjects: 0
Study 8135686 — intervention group
Group type: EXPERIMENTAL
Intervention: Media influence on attitudes
Number of subjects: 0
Study 3689614 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine 0.8 mg (group A)
Number of subjects: 20
Study 3689614 — intervention group
Group type: COMPARATOR
Intervention: i.m. papaveretum 10 mg (group B)
Number of subjects: 20
Study 3689614 — intervention group
Group type: COMPARATOR
Intervention: Control gastric emptying rates (before surgery)
Number of subjects: 20
Study 29451991 — intervention group
Group type: EXPERIMENTAL
Intervention: βHB (d‐β‐hydroxybutyrate) beverage (11.38 g)
Number of subjects: 15
Study 29451991 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) beverage
Number of subjects: 15
Study 29451991 — intervention group
Group type: EXPERIMENTAL
Intervention: βHB (d‐β‐hydroxybutyrate) beverage
Number of subjects: 15
Study 26655163 — intervention group
Group type: EXPERIMENTAL
Intervention: CP‐Trp mixture
Number of subjects: 29
Study 26655163 — intervention group
Group type: EXPERIMENTAL
Intervention: CP+Trp mixture
Number of subjects: 29
Study 26655163 — intervention group
Group type: COMPARATOR
Intervention: CP‐Trp
Number of subjects: 29
Study 24610088 — intervention group
Group type: EXPERIMENTAL
Intervention: HF scissors (HF+ group)
Number of subjects: 35
Study 24610088 — intervention group
Group type: COMPARATOR
Intervention: Control group (CONV)
Number of subjects: 35
Study 22456803 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics
Number of subjects: 84
Study 22456803 — intervention group
Group type: COMPARATOR
Intervention: Supportive treatment only
Number of subjects: 84
Study 20130660 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin
Number of subjects: 12
Study 20130660 — intervention group
Group type: COMPARATOR
Intervention: 56HFCS
Number of subjects: 12
Study 20130660 — intervention group
Group type: COMPARATOR
Intervention: 80HFCS
Number of subjects: 12
Study 18687261 — intervention group
Group type: EXPERIMENTAL
Intervention: Various health promotion interventions based on theories such as Transtheoretical Model, Motivational Interviewing, Social Learning and Social Cognitive Theory, Theory of Planned Behavior, and Cognitive Behavioral Theory
Number of subjects: 0
Study 16552319 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-driven strategies targeting access to healthcare, health and wellness, screening, and tobacco use
Number of subjects: 0
Study 16552319 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based system for collecting process data and random telephone surveys
Number of subjects: 0
Study 12523893 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 681
Study 12523893 — intervention group
Group type: COMPARATOR
Intervention: CMV retinitis
Number of subjects: 681
Study 11193281 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III concentrates
Number of subjects: 0
Study 11193281 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein C and tissue factor-pathway inhibitor
Number of subjects: 0
Study 9033197 — intervention group
Group type: EXPERIMENTAL
Intervention: multidrug regimens
Number of subjects: 215
Study 9033197 — intervention group
Group type: EXPERIMENTAL
Intervention: maximal regimen including daily clofazimine
Number of subjects: 215
Study 9033197 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone
Number of subjects: 215
Study 9033197 — intervention group
Group type: EXPERIMENTAL
Intervention: thalidomide
Number of subjects: 215
Study 9033197 — intervention group
Group type: EXPERIMENTAL
Intervention: maximal regimens including daily rifampicin
Number of subjects: 215
Study 9033197 — intervention group
Group type: EXPERIMENTAL
Intervention: measurements of weight and blood pressure
Number of subjects: 215
Study 1670744 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin (4.7 mg daily)
Number of subjects: 42
Study 1670744 — intervention group
Group type: COMPARATOR
Intervention: Prazosin (6.7 mg daily)
Number of subjects: 42
Study 1670744 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 42
Study 1670744 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 42
Study 6138086 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (15 mg p.o.)
Number of subjects: 19
Study 6138086 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam (15 mg)
Number of subjects: 19
Study 6138086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30944048 — intervention group
Group type: EXPERIMENTAL
Intervention: Force-feeding
Number of subjects: 500
Study 30944048 — intervention group
Group type: COMPARATOR
Intervention: Control (free feeding)
Number of subjects: 500
Study 28355198 — intervention group
Group type: EXPERIMENTAL
Intervention: F130 (130 mg of OPN/L)
Number of subjects: 0
Study 28355198 — intervention group
Group type: EXPERIMENTAL
Intervention: F65 (65 mg of OPN/L)
Number of subjects: 0
Study 28355198 — intervention group
Group type: COMPARATOR
Intervention: SF (Standard Formula)
Number of subjects: 0
Study 25643897 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training prior to aerobic training (RA, n=10)
Number of subjects: 21
Study 25643897 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training after aerobic training (AR, n=11)
Number of subjects: 21
Study 25643897 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RA and AR groups
Number of subjects: 21
Study 25151265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation or silencing of GABAergic neurons or disruption of metabotropic GABA receptor 1 and 2 (GABA B R1/2) signaling in astrocytes
Number of subjects: 0
Study 25151265 — intervention group
Group type: EXPERIMENTAL
Intervention: Developmental depletion of astrocytic GABA B R1/2 signaling
Number of subjects: 0
Study 25151265 — intervention group
Group type: EXPERIMENTAL
Intervention: Ablation of astrocytes
Number of subjects: 0
Study 22300419 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam pharmacokinetics model based on infants, toddlers, and adults (model 1)
Number of subjects: 0
Study 22300419 — intervention group
Group type: COMPARATOR
Intervention: Midazolam pharmacokinetics model based on children and adolescents (model 2)
Number of subjects: 0
Study 19240698 — intervention group
Group type: COMPARATOR
Intervention: NSAID-related injury prevention guidelines
Number of subjects: 0
Study 19240698 — intervention group
Group type: COMPARATOR
Intervention: COX-2 inhibitors
Number of subjects: 0
Study 17721040 — intervention group
Group type: EXPERIMENTAL
Intervention: Existing drugs (e.g., non‐steroidal anti‐inflammatory drugs, vitamins, and imatinib mesylate)
Number of subjects: 0
Study 16586188 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 micrograms 1‐alpha‐hydroxyvitamin D(2) (1‐alpha D(2)) administered daily for 24 months
Number of subjects: 40
Study 16586188 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered daily for 24 months
Number of subjects: 40
Study 16586188 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 micrograms 1‐alpha D(2)
Number of subjects: 40
Study 16586188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12802451 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural biocorrector Namivit
Number of subjects: 0
Study 9858106 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment (n = 18)
Number of subjects: 38
Study 9858106 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea treatment (n = 16)
Number of subjects: 38
Study 9858106 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n = 20)
Number of subjects: 38
Study 9858106 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients (n = 38)
Number of subjects: 38
Study 7890127 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral amino acid preparation causing high plasma amino acid levels
Number of subjects: 27
Study 7890127 — intervention group
Group type: COMPARATOR
Intervention: Parenteral amino acid preparation with normal plasma aminogram levels
Number of subjects: 27
Study 2212504 — intervention group
Group type: COMPARATOR
Intervention: Timoptol 0.5% alone
Number of subjects: 3
Study 2212504 — intervention group
Group type: EXPERIMENTAL
Intervention: Timoptol 0.5%-Pilocarpine 2% (timpilo 2)
Number of subjects: 3
Study 2212504 — intervention group
Group type: EXPERIMENTAL
Intervention: Timoptol 0.5%-Pilocarpine 4% (timpilo 4)
Number of subjects: 3
Study 341946 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 39
Study 341946 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 30304382 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention (14-week lifestyle intervention)
Number of subjects: 133
Study 30304382 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline WBIS scores
Number of subjects: 133
Study 30304382 — intervention group
Group type: EXPERIMENTAL
Intervention: Participant race and WBIS scores interaction
Number of subjects: 133
Study 28185708 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐TCP
Number of subjects: 33
Study 28185708 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐TCP + autogenous bone graft (1:1)
Number of subjects: 33
Study 28185708 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone graft
Number of subjects: 33
Study 26280156 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MMF) 0.1% ointment, applied once daily for 5 days per week for 4 weeks, then on alternate days for 4 weeks, then twice weekly for 4 weeks (group A)
Number of subjects: 64
Study 26280156 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MMF) 0.1% ointment, applied for five consecutive days per week for the entire treatment duration (group B)
Number of subjects: 64
Study 23712068 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 10 cmH2O
Number of subjects: 60
Study 23712068 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 5 cmH2O
Number of subjects: 60
Study 23712068 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PEEP)
Number of subjects: 60
Study 21855160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 44
Study 21855160 — intervention group
Group type: COMPARATOR
Intervention: Medical Nutrition Therapy (MNT)
Number of subjects: 44
Study 18196202 — intervention group
Group type: EXPERIMENTAL
Intervention: PPN-DBS (25 Hz)
Number of subjects: 6
Study 18196202 — intervention group
Group type: EXPERIMENTAL
Intervention: STN-DBS (185 Hz)
Number of subjects: 6
Study 18196202 — intervention group
Group type: EXPERIMENTAL
Intervention: PPN-DBS plus STN-DBS
Number of subjects: 6
Study 18196202 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 9)
Number of subjects: 6
Study 18196202 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 6
Study 18196202 — intervention group
Group type: EXPERIMENTAL
Intervention: DBS (both PPN and STN)
Number of subjects: 6
Study 16021530 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation at 80 mg
Number of subjects: 160
Study 16021530 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation at 200 mg
Number of subjects: 160
Study 16021530 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation at 400 mg
Number of subjects: 160
Study 16021530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 12548078 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (10 mg/d) for 14 days
Number of subjects: 24
Study 12548078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11132252 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous porcine secretin
Number of subjects: 95
Study 11132252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 8936626 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 101
Study 1390473 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocervical sampling with the Kevorkian curette
Number of subjects: 100
Study 1390473 — intervention group
Group type: COMPARATOR
Intervention: Endocervical sampling with the Medscand endocervical brush
Number of subjects: 100
Study 3847486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime (50 mg/kg/dose every 6 hours)
Number of subjects: 50
Study 3847486 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (ampicillin and chloramphenicol in standard doses)
Number of subjects: 50
Study 3847486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 50
Study 3847486 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 50
Study 3847486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime and Standard therapy
Number of subjects: 50
Study 31275607 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led comorbidity counselling
Number of subjects: 769
Study 29558837 — intervention group
Group type: EXPERIMENTAL
Intervention: Introduction of eggs into infants' diets
Number of subjects: 0
Study 29558837 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative research and social marketing component
Number of subjects: 0
Study 26918330 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii (probiotic)
Number of subjects: 39
Study 26918330 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 39
Study 24792735 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK
Number of subjects: 871
Study 24792735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 871
Study 21707914 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary autologous freshly isolated bone marrow cells transplantation (BMCs‐Tx)
Number of subjects: 62
Study 21707914 — intervention group
Group type: COMPARATOR
Intervention: Control group without cell therapy
Number of subjects: 62
Study 19545209 — intervention group
Group type: EXPERIMENTAL
Intervention: Circumcision
Number of subjects: 2655
Study 19545209 — intervention group
Group type: COMPARATOR
Intervention: Control (uncircumcised)
Number of subjects: 2655
Study 17293188 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (10 mg/day)
Number of subjects: 40
Study 17293188 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 17293188 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 40
Study 15223093 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 34
Study 15223093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 11213857 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS)
Number of subjects: 0
Study 9860783 — intervention group
Group type: EXPERIMENTAL
Intervention: GP IIb/IIIa inhibitors
Number of subjects: 32135
Study 7979853 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray (0.5 mg per single spray)
Number of subjects: 248
Study 7979853 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 248
Study 7979853 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine nasal spray
Number of subjects: 248
Study 2472275 — intervention group
Group type: EXPERIMENTAL
Intervention: MFL (methotrexate-5-FU with leucovorin rescue)
Number of subjects: 44
Study 2472275 — intervention group
Group type: COMPARATOR
Intervention: 5-FU (5-fluorouracil)
Number of subjects: 44
Study 2472275 — intervention group
Group type: EXPERIMENTAL
Intervention: MFL
Number of subjects: 44
Study 2472275 — intervention group
Group type: COMPARATOR
Intervention: 5-FU
Number of subjects: 44
Study 4916870 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (single oral dose)
Number of subjects: 211
Study 4916870 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (single dose)
Number of subjects: 211
Study 4916870 — intervention group
Group type: COMPARATOR
Intervention: Piperazine citrate (single dose)
Number of subjects: 211
Study 4916870 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 211
Study 29072026 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Number of subjects: 40
Study 29072026 — intervention group
Group type: COMPARATOR
Intervention: Standard orthotics
Number of subjects: 40
Study 27998967 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 51